Our mission is to develop, manufacture, and market a targeted, proprietary means of preventing anti-drug antibodies in NHP during the testing of biotherapeutics. Our approach will:
- Improve the robustness and quality of preclinical PK and Toxicology testing
- Reduce the cost of NHP testing
- Advance the 3Rs
Our preclinical platform is founded on the clinical research findings of our scientific founder, an internationally recognized expert in the field of immunology and ADA, and his recognition of the importance of extending those results to the preclinical testing of biotherapeutics in NHP in order to both improve testing and promote animal welfare.
In preclinical and clinical studies respectively, it was demonstrated that anti-X abolished the production of cytokines important for antibody production and blocked the response to the Hepatitis A and B vaccines without increasing the risk of infection or other adverse events.
Our business team has a proven record of successful business development, having founded and played key management roles in a number of international startups including:
Space Partnership International (“SPI”), LLC, a hands-on management-consulting group with deep, end-to-end expertise across business, regulatory, engineering and risk management disciplines, helping governments and companies to develop, implement and grow their own space-based scientific research, telecommunications, Earth observation and Weather systems (www.spacepi.com);
Assure Space, which is now a major provider of space insurance capacity for launch and in-orbit risks (www.assure-space.com), and recently sold to AmTrust, a multi-billion dollar insurance company;
Driversiti, a proprietary mobile-based platform that uses the sensors in smartphones and tablets to deliver Situational Awareness to drivers (www.driversiti.com);
AfriHUB, which over the past 10 years has become the largest human capacity building business in West Africa, having trained more than more than 1.5 million students in IT career paths based on internationally accepted testing (www.AfriHub.com).
Jack A. Ragheb, M.D. Ph.D.
Dr. Ragheb is JoMoCo's Scientific Founder and Advisor. He is presently the Senior Medical Fellow for Immunology in Global Patient Safety at Eli Lilly & Co*. Prior to founding JoMoCo, he was Chief Medical Research Officer in the Laboratory of Immunology of the Office of Biotechnology Products at the Food and Drug Administration (FDA). While there, he observed the adverse impact that anti-drug antibodies (ADA) had on the outcomes of both preclinical and clinical studies. Capitalizing on observations he’d made as a Senior Clinical Investigator in the Laboratory of Immunology at the National Institutes of Health, he developed a selective method to effectively prevent the development of ADA in nonhuman primates.
Dr. Ragheb is a graduate of the Johns Hopkins University and School of Medicine. His work and publications have spanned the fields of retrovirology, gene therapy, immune activation, and clinical trials in immune tolerance. A diplomate of the American Board of Allergy and Immunology, he continues to see patients in the Experimental Transplantation and Immunology Branch of the National Cancer Institute at the NIH*.
*information for affiliation purposes only
Mr. Eid is a seasoned executive with over 25 years experience in establishing, managing and growing technology-related companies in the US, Europe, Asia and Africa. He is co-founder of JoMoCo-AMR where is responsible for overseeing all financial, capital market and business development activities.
As a founding member of Space Partnership International, LLC, Mr. Eid’s continues to provide business development, financial, risk management services for the investment, insurance communities and commercial start-ups.
Mr. Eid began his career in the financial division of Arianespace Inc. Subsequent to Ariane, Mr. Eid was engaged in finance, space insurance and risk management activities first with International Space Brokers (Willis), and later as a Managing Director for Aon. In addition he founded and played key management roles in a number of international startups, including Assure Space, which is now a major provider of space insurance capacity for launch and in-orbit risks (www.assure-space.com), and recently sold to AmTrust, a multi-billion dollar insurance company; Driversiti, a proprietary mobile-based platform that uses the sensors in smartphones and tablets to deliver Situational Awareness to drivers (www.driversiti.com);
Mr. Eid holds an M.B.A. degree in International Finance from George Washington University and a B.S. in Business Administration from Georgetown University.
Shafiq Ahmad Chaudhuri
Mr. Chaudhuri brings to JoMoCo over 40 years of international corporate experience having projects in 32 countries. His current focus is on the Asian growth markets where he was involved in setting up a CRO and CMO in Bangladesh. He maintains strong relationships with the largest pharmaceutical companies in Bangladesh; Beximco, Square Group, Glaxo Smith Kline, Incepta, icddrb and Government Science Lab. Among his many accomplishments, Mr. Chaudhuri was involved in Telemedicine with the US Allied forces during the Gulf War.
Mr. Chaudhuri held senior management positions, at General Electric Co., COMSAT Corporation, Mobile Telesystems, Inc. (MTI), Taylor McKenzie, Inc. and Nomad Digital. He worked with US EX-IM Bank, VCs and as “lender’s engineer” while at Taylor McKenzie.
Mr. Chaudhuri holds an MSEE in Communications from The George Washington University, B.Sc. (Honours) EEE degree from The University of Birmingham, UK; and a Certificate on Negotiations from Harvard. Former Chairman of Mobile Satellite Users Assoc. (MSUA), past member of US Dept. of Commerce Export Council, and a founding Board Member of USBAC, an NGO advising The Bangladesh Caucus at US Congress on policy relating to Bangladesh.
Business Development and Marketing